In his extensive overview of the evidence supporting the use of novel peroxisome proliferator-activated receptor (PPAR) agonists in the treatment of hypertriglyceridaemia, Professor Bart Staels describes mechanisms of action and therapeutic activities of these agents before focusing on pre-clinical and clinical data relating to the selective PPARα (SPPARMα) modulator, pemafibrate.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
